KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Supernus Pharmaceuticals (SUPN) Tax Provisions: 2010-2024

Historic Tax Provisions for Supernus Pharmaceuticals (SUPN) over the last 13 years, with Dec 2024 value amounting to $24.0 million.

  • Supernus Pharmaceuticals' Tax Provisions fell 299.15% to -$12.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.7 million, marking a year-over-year decrease of 113.00%. This contributed to the annual value of $24.0 million for FY2024, which is 1552.10% up from last year.
  • Per Supernus Pharmaceuticals' latest filing, its Tax Provisions stood at $24.0 million for FY2024, which was up 1,552.10% from $1.5 million recorded in FY2023.
  • In the past 5 years, Supernus Pharmaceuticals' Tax Provisions ranged from a high of $41.7 million in FY2020 and a low of $32,000 during FY2022.
  • In the last 3 years, Supernus Pharmaceuticals' Tax Provisions had a median value of $1.5 million in 2023 and averaged $8.5 million.
  • In the last 5 years, Supernus Pharmaceuticals' Tax Provisions tumbled by 99.84% in 2022 and then surged by 4,440.62% in 2023.
  • Over the past 5 years, Supernus Pharmaceuticals' Tax Provisions (Yearly) stood at $41.7 million in 2020, then slumped by 52.63% to $19.8 million in 2021, then plummeted by 99.84% to $32,000 in 2022, then soared by 4,440.62% to $1.5 million in 2023, then skyrocketed by 1,552.10% to $24.0 million in 2024.